US Patent Issued to Amgen on Aug. 19 for "Synthesis of key intermediate of KRAS G12C inhibitor compound" (Massachusetts, California Inventors)

ALEXANDRIA, Va., Aug. 20 -- United States Patent no. 12,391,689, issued on Aug. 19, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"Synthesis of key intermediate of KRAS G12C inhibitor compound" was invented by Andrew Thomas Parsons (Cambridge, Mass.), Brian McNeil Cochran (San Diego), William Powazinik IV (Thousand Oaks, Calif.) and Marc Anthony Caporini (Belmont, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structureuseful for the synthesis of compounds that target KRAS G12C mutations, such as"

The patent was filed on March 8, 2022, under Application No....